Latest Breaking News On - Rigel pharmaceuticals - Page 7 : comparemela.com

After Roche breakup, Blueprint Medicines finds Gavreto a new home at Rigel

After Roche breakup, Blueprint Medicines finds Gavreto a new home at Rigel
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United statesRoche genentechEli lillyRigel rezlidhiaDave santosRigel pharmaceuticalsMerck coBlueprint medicinesBig pharmaGreat chinaRoyalty pharmaForma therapeutics

Rigel Pharma Acquires US Rights To Gavreto From Blueprint Medicines; Stock Up In Pre-Market

Rigel Pharmaceuticals, Inc. (RIGL), Thursday announced that it has agreed to acquire the U.S. rights to Gavreto from Blueprint Medicines Corp. for an initial payment of $10 million, followed by an additional $5 million after one year of the closing date.

Rigel pharmaceuticals incBlueprint medicines corpRigel pharmaceuticalsBlueprint medicines

Rigel takes on US marketing of Blueprint s Gavreto

Blueprint Medicines Corp. found a new U.S. commercialization home for Gavreto (pralsetinib) through an agreement with Rigel Pharmaceuticals Inc. potentially worth $117.5 million, now that Roche Holding AG has relinquished all rights.

Blueprint medicines corpRoche holdingRigel pharmaceuticals incBlueprint medicinesRigel pharmaceuticalsBlueprint medicines corpRigel pharmaceuticals incRoche holding agNon small cell lung cancerDeals andm amp aRet inhibitorMedullary thyroid cancer

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBiotoscana farmaArvind utchanahSamira sakhiaKnight therapeutics incRigel pharmaceuticals incTherapeutics incUnited medical ltdaLatin americaChief executive officerKnight therapeuticsRigel pharmaceuticalsLatin americanUnited medicalAnnual reportAnnual information form

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

MONTREAL, Feb. 21, 2024 Knight Therapeutics Inc., a pan-American specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a.

United statesArvind utchanahBiotoscana farmaSamira sakhiaRigel pharmaceuticals incKnight therapeutics incTherapeutics incUnited medical ltdaLatin americaChief executive officerKnight therapeuticsRigel pharmaceuticalsLatin americanUnited medicalAnnual reportAnnual information form